Inhibiting fatty acid amide hydrolase normalizes endotoxin-induced enhanced gastrointestinal motility in mice

British Journal of Pharmacology

Volumn 165, Issue 5, 2012, Pages 1556-1571

  Bashashati, M ^a   Storr, M A ^b   Nikas, S P ^c   Wood, J T ^c   Godlewski, G ^d   Liu, J ^d   Ho, W ^a   Keenan, C M ^a   Zhang, H ^a   Alapafuja, S O ^c   Cravatt, B F ^e   Lutz, B ^f   MacKie, K ^g   Kunos, G ^d   Patel, K D ^a   Makriyannis, A ^c   Davison, J S ^a   Sharkey, K A ^a  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c NORTHEASTERN UNIVERSITY   (United States)

^d NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

^e SCRIPPS RESEARCH INSTITUTE   (United States)

^f JOHANNES GUTENBERG UNIVERSITY   (Germany)

^g INDIANA UNIVERSITY   (United States)

Author keywords

cannabinoid receptors; endocannabinoids; fatty acid amide hydrolase; gastrointestinal motility; lipopolysaccharide

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 1 DEOXY 3 (1,1 DIMETHYLBUTYL) DELTA8 TETRAHYDROCANNABINOL; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 6 IODO 3 (4 METHOXYBENZOYL) 2 METHYL 1 (2 MORPHOLINOETHYL)INDOLE; AM 3506; ANANDAMIDE; BETHANECHOL; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID RECEPTOR ANTAGONIST; CYCLOHEXYLCARBAMIC ACID 3' CARBAMOYLBIPHENYL 3 YL ESTER; ENDOTOXIN; ETHANOLAMINE; FATTY ACID AMIDASE; FATTY ACID AMIDASE INHIBITOR; LIPOPOLYSACCHARIDE; MESSENGER RNA; PLACEBO; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOTRANSFORMATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; EVOKED MUSCLE RESPONSE; FECES LEVEL; GASTROINTESTINAL MOTILITY; GASTROINTESTINAL MOTILITY DISORDER; ILEUM; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; INTESTINE CONTRACTION; INTESTINE TRANSIT TIME; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; QUANTITATIVE STUDY; REAL TIME POLYMERASE CHAIN REACTION; SMOOTH MUSCLE CONTRACTILITY;

ALKANESULFONATES; AMIDOHYDROLASES; ANIMALS; COLON; ENDOTOXINS; ENTERIC NERVOUS SYSTEM; GASTROINTESTINAL MOTILITY; ILEUM; INFLAMMATION; LIPOPOLYSACCHARIDES; MALE; MICE; MICE, INBRED C57BL; MOTOR ACTIVITY; PHENOLS; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2;

EID: 84863115452     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2011.01644.x     Document Type: Article

References (68)

1. Ahn K, McKinney MK, Cravatt BF, (2008). Enzymatic pathways that regulate endocannabinoid signaling in the nervous system. Chem Rev 108: 1687-1707.
2. Aviello G, Romano B, Izzo AA, (2008). Cannabinoids and gastrointestinal motility: animal and human studies. Eur Rev Med Pharmacol Sci 12 (Suppl. 1): 81-93.
3. Camilleri M, Carlson P, McKinzie S, Grudell A, Busciglio I, Burton D, et al,. (2008). Genetic variation in endocannabinoid metabolism, gastrointestinal motility, and sensation. Am J Physiol Gastrointest Liver Physiol 294: G13-G19.
4. Capasso R, Izzo AA, Fezza F, Pinto A, Capasso F, Mascolo N, et al,. (2001). Inhibitory effect of palmitoylethanolamide on gastrointestinal motility in mice. Br J Pharmacol 134: 945-950.
5. Capasso R, Matias I, Lutz B, Borrelli F, Capasso F, Marsicano G, et al,. (2005). Fatty acid amide hydrolase controls mouse intestinal motility in vivo. Gastroenterology 129: 941-951.
6. Capasso R, Borrelli F, Aviello G, Romano B, Scalisi C, Capasso F, et al,. (2008). Cannabidiol, extracted from Cannabis sativa, selectively inhibits inflammatory hypermotility in mice. Br J Pharmacol 154: 1001-1008.
7. Ceregrzyn M, Kamata T, Yajima T, Kuwahara A, (2001). Biphasic alterations in gastrointestinal transit following endotoxaemia in mice. Neurogastroenterol Motil 13: 605-613.
8. Chang L, Luo L, Palmer JA, Sutton S, Wilson SJ, Barbier AJ, et al,. (2006). Inhibition of fatty acid amide hydrolase produces analgesia by multiple mechanisms. Br J Pharmacol 148: 102-113.
9. Cianchi F, Papucci L, Schiavone N, Lulli M, Magnelli L, Vinci MC, et al,. (2008). Cannabinoid receptor activation induces apoptosis through tumor necrosis factor alpha-mediated ceramide de novo synthesis in colon cancer cells. Clin Cancer Res 14: 7691-7700.
10. Cluny NL, Keenan CM, Lutz B, Piomelli D, Sharkey KA, (2009). The identification of peroxisome proliferator-activated receptor alpha-independent effects of oleoylethanolamide on intestinal transit in mice. Neurogastroenterol Motil 21: 420-429.
11. Cravatt BF, Lichtman AH, (2002). The enzymatic inactivation of the fatty acid amide class of signaling lipids. Chem Phys Lipids 121: 135-148.
12. Cravatt BF, Lichtman AH, (2003). Fatty acid amide hydrolase: an emerging therapeutic target in the endocannabinoid system. Curr Opin Chem Biol 7: 469-475.
13. Cravatt BF, Demarest K, Patricelli MP, Bracey MH, Giang DK, Martin BR, et al,. (2001). Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc Natl Acad Sci USA 98: 9371-9376.
14. Darmani NA, McClanahan BA, Trinh C, Petrosino S, Valenti M, Di Marzo, (2005). Cisplatin increases brain 2-arachidonoylglycerol (2-AG) and concomitantly reduces intestinal 2-AG and anandamide levels in the least shrew. Neuropharmacology 49: 502-513.
15. De Filippis D, Iuvone T, D'Amico A, Esposito G, Steardo L, Herman AG, et al,. (2008a). Effect of cannabidiol on sepsis-induced motility disturbances in mice: involvement of CB receptors and fatty acid amide hydrolase. Neurogastroenterol Motil 20: 919-927.
16. De Filippis D, Iuvone T, Esposito G, Steardo L, Arnold GH, Paul AP, et al,. (2008b). Melatonin reverses lipopolysaccharide-induced gastro-intestinal motility disturbances through the inhibition of oxidative stress. J Pineal Res 44: 45-51.
17. De Petrocellis L, Ligresti A, Moriello AS, Allara M, Bisogno T, Petrosino S, et al,. (2011). Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. Br J Pharmacol 163: 1479-1494.
18. Deutsch DG, Lin S, Hill WA, Morse KL, Salehani D, Arreaza G, et al,. (1997). Fatty acid sulfonyl fluorides inhibit anandamide metabolism and bind to the cannabinoid receptor. Biochem Biophys Res Commun 231: 217-221.
19. Di Marzo V, (2009). The endocannabinoid system: its general strategy of action, tools for its pharmacological manipulation and potential therapeutic exploitation. Pharmacol Res 60: 77-84.
20. Duncan M, Davison JS, Sharkey KA, (2005). Review article: endocannabinoids and their receptors in the enteric nervous system. Aliment Pharmacol Ther 22: 667-683.
21. Duncan M, Mouihate A, Mackie K, Keenan CM, Buckley NE, Davison JS, et al,. (2008). Cannabinoid CB2 receptors in the enteric nervous system modulate gastrointestinal contractility in lipopolysaccharide-treated rats. Am J Physiol Gastrointest Liver Physiol 295: G78-G87.
22. Fegley D, Gaetani S, Duranti A, Tontini A, Mor M, Tarzia G, et al,. (2005). Characterization of the fatty acid amide hydrolase inhibitor cyclohexyl carbamic acid 3′-carbamoyl-biphenyl-3-yl ester (URB597): effects on anandamide and oleoylethanolamide deactivation. J Pharmacol Exp Ther 313: 352-358.
23. Fezza F, De Simone C, Amadio D, Maccarrone M, (2008). Fatty acid amide hydrolase: a gate-keeper of the endocannabinoid system. Subcell Biochem 49: 101-132.
24. Fowler CJ, Borjesson M, Tiger G, (2000). Differences in the pharmacological properties of rat and chicken brain fatty acid amidohydrolase. Br J Pharmacol 131: 498-504.
25. Gaetani S, Cuomo V, Piomelli D, (2003). Anandamide hydrolysis: a new target for anti-anxiety drugs? Trends Mol Med 9: 474-478.
26. Gershon MD, (2005). Nerves, reflexes, and the enteric nervous system: pathogenesis of the irritable bowel syndrome. J Clin Gastroenterol 39: S184-S193.
27. Godlewski G, Alapafuja SO, Batkai S, Nikas SP, Cinar R, Offertaler L, et al,. (2010). Inhibitor of fatty acid amide hydrolase normalizes cardiovascular function in hypertension without adverse metabolic effects. Chem Biol 17: 1256-1266.
28. Gomez R, Navarro M, Ferrer B, Trigo JM, Bilbao A, Del Arco I, et al,. (2002). A peripheral mechanism for CB1 cannabinoid receptor-dependent modulation of feeding. J Neurosci 22: 9612-9617.
29. Helliwell RJ, Chamley LW, Blake-Palmer K, Mitchell MD, Wu J, Kearn CS, et al,. (2004). Characterization of the endocannabinoid system in early human pregnancy. J Clin Endocrinol Metab 89: 5168-5174.
30. Izzo AA, Camilleri M, (2008). Emerging role of cannabinoids in gastrointestinal and liver diseases: basic and clinical aspects. Gut 57: 1140-1155.
31. Izzo AA, Sharkey KA, (2010). Cannabinoids and the gut: new developments and emerging concepts. Pharmacol Ther 126: 21-38.
32. Izzo AA, Aviello G, Petrosino S, Orlando P, Marsicano G, Lutz B, et al,. (2008). Increased endocannabinoid levels reduce the development of precancerous lesions in the mouse colon. J Mol Med 86: 89-98.
33. Katayama K, Ueda N, Kurahashi Y, Suzuki H, Yamamoto S, Kato I, (1997). Distribution of anandamide amidohydrolase in rat tissues with special reference to small intestine. Biochim Biophys Acta 1347: 212-218.
34. Kathuria S, Gaetani S, Fegley D, Valino F, Duranti A, Tontini A, et al,. (2003). Modulation of anxiety through blockade of anandamide hydrolysis. Nat Med 9: 76-81.
35. Krawisz JE, Sharon P, Stenson WF, (1984). Quantitative assay for acute intestinal inflammation based on myeloperoxidase activity. Assessment of inflammation in rat and hamster models. Gastroenterology 87: 1344-1350.
36. Lee SF, Newton C, Widen R, Friedman H, Klein TW, (2001). Downregulation of cannabinoid receptor 2 (CB2) messenger RNA expression during in vitro stimulation of murine splenocytes with lipopolysaccharide. Adv Exp Med Biol 493: 223-228.
37. Li YY, Li YN, Ni JB, Chen CJ, Lv S, Chai SY, et al,. (2010). Involvement of cannabinoid-1 and cannabinoid-2 receptors in septic ileus. Neurogastroenterol Motil 22: 350-e88.
38. Ligresti A, Bisogno T, Matias I, De Petrocellis L, Cascio MG, Cosenza V, et al,. (2003). Possible endocannabinoid control of colorectal cancer growth. Gastroenterology 125: 677-687.
39. Liu J, Batkai S, Pacher P, Harvey-White J, Wagner JA, Cravatt BF, et al,. (2003). Lipopolysaccharide induces anandamide synthesis in macrophages via CD14/MAPK/phosphoinositide 3-kinase/NF-kappaB independently of platelet-activating factor. J Biol Chem 278: 45034-45039.
40. Maccarrone M, De Petrocellis L, Bari M, Fezza F, Salvati S, Di Marzo V, et al,. (2001). Lipopolysaccharide downregulates fatty acid amide hydrolase expression and increases anandamide levels in human peripheral lymphocytes. Arch Biochem Biophys 393: 321-328.
41. Maione S, De Petrocellis L, de Novellis V, Moriello AS, Petrosino S, Palazzo E, et al,. (2007). Analgesic actions of N-arachidonoyl-serotonin, a fatty acid amide hydrolase inhibitor with antagonistic activity at vanilloid TRPV1 receptors. Br J Pharmacol 150: 766-781.
42. Makwana R, Molleman A, Parsons ME, (2010). Evidence for both inverse agonism at the cannabinoid CB1 receptor and the lack of an endogenous cannabinoid tone in the rat and guinea-pig isolated ileum myenteric plexus-longitudinal muscle preparation. Br J Pharmacol 160: 615-626.
43. Marquez L, Suarez J, Iglesias M, Bermudez-Silva FJ, Rodriguez FF, Andreu M, (2009). Ulcerative colitis induces changes on the expression of the endocannabinoid system in the human colonic tissue. PLoS ONE 4: e6893.
44. Marsicano G, Wotjak CT, Azad SC, Bisogno T, Rammes G, Cascio MG, et al,. (2002). The endogenous cannabinoid system controls extinction of aversive memories. Nature 418: 530-534.
45. Massa F, Marsicano G, Hermann H, Cannich A, Monory K, Cravatt BF, et al,. (2004). The endogenous cannabinoid system protects against colonic inflammation. J Clin Invest 113: 1202-1209.
46. Mathison R, Ho W, Pittman QJ, Davison JS, Sharkey KA, (2004). Effects of cannabinoid receptor-2 activation on accelerated gastrointestinal transit in lipopolysaccharide-treated rats. Br J Pharmacol 142: 1247-1254.
47. Moreira FA, Kaiser N, Monory K, Lutz B, (2008). Reduced anxiety-like behaviour induced by genetic and pharmacological inhibition of the endocannabinoid-degrading enzyme fatty acid amide hydrolase (FAAH) is mediated by CB1 receptors. Neuropharmacology 54: 141-150.
48. Mule F, Amato A, Baldassano S, Serio R, (2007a). Evidence for a modulatory role of cannabinoids on the excitatory NANC neurotransmission in mouse colon. Pharmacol Res 56: 132-139.
49. Mule F, Amato A, Serio R, (2007b). Role for NK(1) and NK(2) receptors in the motor activity in mouse colon. Eur J Pharmacol 570: 196-202.
50. Ochoa-Cortes F, Ramos-Lomas T, Miranda-Morales M, Spreadbury I, Ibeakanma C, Barajas-Lopez C, et al,. (2010). Bacterial cell products signal to mouse colonic nociceptive dorsal root ganglia neurons. Am J Physiol Gastrointest Liver Physiol 299: G723-G732.
51. Ohman L, Simren M, (2010). Pathogenesis of IBS: role of inflammation, immunity and neuroimmune interactions. Nat Rev Gastroenterol Hepatol 7: 163-173.
52. Petrosino S, Di Marzo V, (2010). FAAH and MAGL inhibitors: therapeutic opportunities from regulating endocannabinoid levels. Curr Opin Investig Drugs 11: 51-62.
53. Pinto L, Izzo AA, Cascio MG, Bisogno T, Hospodar-Scott K, Brown DR, et al,. (2002). Endocannabinoids as physiological regulators of colonic propulsion in mice. Gastroenterology 123: 227-234.
54. Puffenbarger RA, (2005). Molecular biology of the enzymes that degrade endocannabinoids. Curr Drug Targets CNS Neurol Disord 4: 625-631.
55. Scherma M, Medalie J, Fratta W, Vadivel SK, Makriyannis A, Piomelli D, et al,. (2008). The endogenous cannabinoid anandamide has effects on motivation and anxiety that are revealed by fatty acid amide hydrolase (FAAH) inhibition. Neuropharmacology 54: 129-140.
56. Schlosburg JE, Kinsey SG, Lichtman AH, (2009). Targeting fatty acid amide hydrolase (FAAH) to treat pain and inflammation. AAPS J 11: 39-44.
57. Storr MA, Sharkey KA, (2007). The endocannabinoid system and gut-brain signalling. Curr Opin Pharmacol 7: 575-582.
58. Storr MA, Keenan CM, Emmerdinger D, Zhang H, Yuce B, Sibaev A, et al,. (2008). Targeting endocannabinoid degradation protects against experimental colitis in mice: involvement of CB1 and CB2 receptors. J Mol Med 86: 925-936.
59. Storr M, Emmerdinger D, Diegelmann J, Yuce B, Pfennig S, Ochsenkuhn T, et al,. (2009a). The role of fatty acid hydrolase gene variants in inflammatory bowel disease. Aliment Pharmacol Ther 29: 542-551.
60. Storr MA, Keenan CM, Zhang H, Patel KD, Makriyannis A, Sharkey KA, (2009b). Activation of the cannabinoid 2 receptor (CB(2)) protects against experimental colitis. Inflamm Bowel Dis 15: 1678-1685.
61. Ueda N, Yamanaka K, Yamamoto S, (2001). Purification and characterization of an acid amidase selective for N-palmitoylethanolamine, a putative endogenous anti-inflammatory substance. J Biol Chem 276: 35552-35557.
62. Williams J, Pandarinathan L, Wood J, Vouros P, Makriyannis A, (2006). Endocannabinoid metabolomics: a novel liquid chromatography-mass spectrometry reagent for fatty acid analysis. AAPS J 8: E655-E660.
63. Williams J, Wood J, Pandarinathan L, Karanian DA, Bahr BA, Vouros P, et al,. (2007). Quantitative method for the profiling of the endocannabinoid metabolome by LC-atmospheric pressure chemical ionization-MS. Anal Chem 79: 5582-5593.
64. de Winter BY, van Nassauw L, de Man JG, de Jonge F, Bredenoord AJ, Seerden TC, et al,. (2005). Role of oxidative stress in the pathogenesis of septic ileus in mice. Neurogastroenterol Motil 17: 251-261.
65. Wise LE, Cannavacciulo R, Cravatt BF, Martin BF, Lichtman AH, (2008). Evaluation of fatty acid amides in the carrageenan-induced paw edema model. Neuropharmacology 54: 181-188.
66. Wood JT, Williams JS, Pandarinathan L, Courville A, Keplinger MR, Janero DR, et al,. (2008). Comprehensive profiling of the human circulating endocannabinoid metabolome: clinical sampling and sample storage parameters. Clin Chem Lab Med 46: 1289-1295.
67. Wright K, Rooney N, Feeney M, Tate J, Robertson D, Welham M, et al,. (2005). Differential expression of cannabinoid receptors in the human colon: cannabinoids promote epithelial wound healing. Gastroenterology 129: 437-453.
68. Wright KL, Duncan M, Sharkey KA, (2008). Cannabinoid CB2 receptors in the gastrointestinal tract: a regulatory system in states of inflammation. Br J Pharmacol 153: 263-270.